See our latest analysis for Teva Pharmaceutical Industries.
Zooming out to the bigger picture, Teva’s share price has staged an impressive comeback lately, even as long-term total shareholder returns reveal just how much momentum has grown. Over the past year, the share price return is still in slightly negative territory, but with a 128% total return over three years and more than 100% over five years, investors who stuck around have been well rewarded. Sentiment shifts and recent price gains point to renewed optimism.
If pharma’s latest moves have you considering what else is on the rise, check out other industry contenders in our curated list in See the full…


